COVID-19 infection in Crohn's disease under treatment with adalimumab

Gut. 2020 Jul;69(7):1364-1365. doi: 10.1136/gutjnl-2020-321240. Epub 2020 Apr 20.

Authors

Antonio Tursi¹, Gioacchino Angarano², Laura Monno², Annalisa Saracino², Fabio Signorile², Aurelia Ricciardi², Alfredo Papa³

Affiliations

¹ Gastroenterology Service, Azienda Sanitaria Locale Barletta Andria Trani, Andria, Puglia, Italy antotursi@tiscali.it.
² Division of Infectious Diseases, Bari University Hospital, University of Bari, Bari, Puglia, Italy.
³ Division of Internal Medicine and Gastroenterology, Complesso Integrato "Columbus", Catholic University of the Sacred Heart Faculty of Medicine and Surgery, Roma, Lazio, Italy.

PMID: 32312788
DOI: 10.1136/gutjnl-2020-321240

No abstract available

Keywords: crohn's disease; immune response.

Publication types

Letter
Comment

MeSH terms

Adalimumab
Betacoronavirus
COVID-19
Coronavirus Infections
Coronavirus*
Crohn Disease*
Humans
Pandemics
Pneumonia, Viral
SARS-CoV-2

Substances

Adalimumab